Cingulate Receives A European Patent For Its Lead Asset CTx-1301 (Dexmethylphenidate) For Treatment Of Attention Deficit Hyperactivity Disorder
Portfolio Pulse from Benzinga Newsdesk
Cingulate has received a European patent for its lead asset CTx-1301 (Dexmethylphenidate) for the treatment of ADHD. The patent, granted on August 14, 2024, covers up to 30 European territories, including the UK. Cingulate also holds patents in Australia, Canada, and Israel, with pending patents in Hong Kong, South Korea, and the US.
August 15, 2024 | 11:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cingulate has received a European patent for its lead asset CTx-1301 for ADHD treatment, covering up to 30 European territories including the UK. This strengthens Cingulate's intellectual property portfolio and could enhance its market position in Europe.
The European patent for CTx-1301 significantly strengthens Cingulate's intellectual property portfolio, potentially enhancing its market position and revenue prospects in Europe. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100